REG - Scancell Hlds - Notice of AGM

Scancell HoldingsAnnouncement

01/10/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241001:nRSA3234Ga&default-theme=true

RNS Number : 3234G  Scancell Holdings Plc  01 October 2024

1 October 2024

 

Scancell Holdings plc

("Scancell" or the "Company")

 

Notice of Annual General Meeting

 

 

Scancell Holdings plc (AIM: SCLP), the developer of novel immunotherapies for
the treatment of cancer, announces that the Company's Annual Report and
Accounts for the year ended 30 April 2024 and Notice of Annual General Meeting
("AGM") will be sent to shareholders shortly.

 

The Annual Report and Accounts for the year ended 30 April 2024 is available
on the Company's website at
https://www.scancell.co.uk/investors/financial-info
(https://www.scancell.co.uk/investors/financial-info) .

 

The AGM will be held at 3.00pm GMT at the offices of Cooley (UK) LLP at 22
Bishopsgate, London, EC2N 4BQ on Friday 25(th) October 2024.

 

After the AGM, Scancell's senior management team will be presenting the final
results for the year ended 30 April 2024 followed by a Q&A session, and
all shareholders are invited to attend in person.

 

-ENDS-

 

 For further information, please contact:

 Scancell Holdings plc                                                    +44 (0) 20 3709 5700
 Professor Lindy Durrant, CEO

 Dr Jean-Michel Cosséry, Non-Executive Chairman

 Panmure Liberum Limited (Nominated Advisor and Joint Broker)             +44 (0) 20 7886 2500
 Emma Earl/ Freddy Crossley/ Will Goode/ Mark Rogers (Corporate Finance)
 Rupert Dearden (Corporate Broking)

 WG Partners LLP (Joint Broker)                                           +44 (0) 20 3705 9330
 David Wilson/ Claes Spang/ Satheesh Nadarajah/ Erland Sternby

 ICR Consilium
 Mary-Jane Elliott/ Angela Gray/ Lindsey Neville                          +44 (0) 20 37095700

                                                                          scancell@consilium-comms.com (mailto:scancell@consilium-comms.com)

 
 

About Scancell

 

Scancell is a clinical stage immunotherapy company that is leveraging its
proprietary research, built up over many years of studying the human adaptive
immune system, to generate novel medicines to treat significant unmet needs in
cancer. The Company is building a pipeline of innovative products by utilising
its four technology platforms: Moditope(®) and ImmunoBody(®) for vaccines
and GlyMab(®) and AvidiMab(®) for antibodies. Adaptive immune responses
include antibodies and T cells (CD4 and CD8), both of which can recognise
damaged or infected cells. In order to destroy such cancerous or infected
cells, Scancell uses either vaccines to induce immune responses or monoclonal
antibodies (mAbs) to redirect immune cells or drugs. The Company's approaches
are that vaccines (ImmunoBody(®) and Moditope(®)) use unique receptors to
target antigens to activated antigen presenting cells whereas its mAb
portfolio targets glycans or sugars that are added onto proteins and / or
lipids (GlyMab(®)) or enhances the potency of antibodies and their ability to
directly kill tumour cells (AvidiMab(®)).

Scancell is headquartered in Oxford, United Kingdom and is listed on AIM
(LSE.SCLP.L). For further information about Scancell, please visit:
https://www.scancell.co.uk. (https://www.scancell.co.uk.)

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NOABLGDCDBXDGSG